Undisputed WWE Title Match Plans for SmackDown in Berlin
- The Inflation Reduction Act of 2022 is a landmark United States federal law enacted on August 16, 2022, encompassing provisions related to healthcare costs, climate change, and tax...
- Signed into law by president Joe Biden, the Act aims to lower healthcare premiums, address climate change through investments in clean energy, and reduce the federal deficit.
- For example, the Congressional Budget Office (CBO) estimated that the Act would reduce the deficit by $305 billion over ten years.
“`html
The Inflation Reduction Act of 2022
Table of Contents
The Inflation Reduction Act of 2022 is a landmark United States federal law enacted on August 16, 2022, encompassing provisions related to healthcare costs, climate change, and tax reform.
Signed into law by president Joe Biden, the Act aims to lower healthcare premiums, address climate change through investments in clean energy, and reduce the federal deficit. It represents a notable legislative achievement for the Biden administration and the Democratic Party, passing through Congress via the budget reconciliation process, allowing it to bypass a Senate filibuster.
For example, the Congressional Budget Office (CBO) estimated that the Act would reduce the deficit by $305 billion over ten years. CBO Report
Key Provisions: Healthcare
The Inflation Reduction Act directly addresses healthcare costs,primarily through allowing Medicare to negotiate prescription drug prices.
Prior to the Act, Medicare was largely prohibited from negotiating drug prices with pharmaceutical companies, leading to higher costs for beneficiaries. The law allows Medicare to negotiate the prices of certain high-cost drugs,starting with a limited number of drugs in 2026 and expanding over time. It also caps out-of-pocket prescription drug costs for Medicare beneficiaries at $2,000 per year, beginning in 2025. Additionally,the Act extends enhanced Affordable Care Act (ACA) subsidies through 2025,preventing premium increases for millions of americans.
The Centers for Medicare & Medicaid services (CMS) released guidance on the drug price negotiation program on August 29, 2023. CMS press Release
Key Provisions: Climate Change
The Inflation Reduction Act allocates approximately $369 billion towards climate and energy programs, representing the largest climate investment in U.S. history.
These investments include tax credits for renewable energy production,electric vehicle purchases,and energy efficiency improvements. The Act also provides funding for climate resilience projects, such as protecting communities from extreme weather events. A key component is the extension and expansion of tax credits for solar and wind energy, aiming to accelerate the transition to a clean energy economy. The law also establishes a Greenhouse Gas Reduction Fund to support projects that reduce greenhouse gas emissions.
The Department of Energy (DOE) announced $2.8 billion in funding for projects to strengthen the domestic supply chain for critical materials needed for clean energy technologies on November 22, 2023. DOE Proclamation
Key Provisions: Tax Reform
The Inflation Reduction Act introduces tax changes aimed at increasing revenue and ensuring that large corporations pay their fair share.
A central provision is a 15% minimum tax on corporations with over $1 billion in profits, designed to prevent companies from avoiding taxes through loopholes. The Act also increases funding for the Internal Revenue Service (IRS) to improve tax enforcement and customer service. These measures are projected to generate significant revenue to offset the costs of the healthcare and climate provisions. The Joint Committee on taxation estimates that the corporate minimum tax will raise over $300 billion over ten years.
The IRS released guidance on the corporate choice minimum tax (CAMT) on December 1, 2023. IRS News Release
Ongoing Developments (as of January 13, 2026)
As of January 13, 2026, the Inflation Reduction Act continues to be implemented, with ongoing legal challenges and administrative actions shaping its impact.
Several lawsuits have been filed challenging various provisions of the Act, particularly those related to drug price negotiation. The Supreme Court heard arguments in Pharmaceutical Research and manufacturers of America v. Becerra on October 11,2025,concerning the constitutionality of the drug price negotiation program. A ruling is expected in Spring 2026.